Zanubrutinib MoA slide kit

Zanubrutinib MoA slide kit
 SLIDE KIT   12   01/2022

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton's Tyrosine Kinase (BTK). It is currently being evaluated in a broad late-stage clinical trials program globally, as a potential monotherapy and in combination with other therapies to treat various B-cell malignancies.

Rating

Rate this resource